Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-Remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT02769767
What this trial is testing

Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Instituto Jalisciense de Cancerologia 500
Post-approval studies (Phase 4)Study completedNCT01623596
What this trial is testing

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Novartis Pharmaceuticals 881
Post-approval studies (Phase 4)Study completedNCT00317941
What this trial is testing

Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Bayer 220
Not applicableLooking for participantsNCT06796504
What this trial is testing

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

Who this might be right for
Relapsing Remitting Multiple Sclerosis
SetPoint Medical Corporation 60
Testing effectiveness (Phase 2)Looking for participantsNCT07827716
What this trial is testing

Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Chuan Qin 100
Testing effectiveness (Phase 2)Study completedNCT01198132
What this trial is testing

A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly

Who this might be right for
Multiple Sclerosis
Merck KGaA, Darmstadt, Germany 129
Not applicableEnded earlyNCT02266121
What this trial is testing

Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple SclerosisSecondary-progressive Multiple SclerosisCognitive Deficits+1 more
University Hospital of Mont-Godinne 100
Testing effectiveness (Phase 2)Study completedNCT00882999
What this trial is testing

Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Eli Lilly and Company 245
Not applicableStudy completedNCT02277964
What this trial is testing

Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University Hospital, Basel, Switzerland 25
Post-approval studies (Phase 4)Study completedNCT00203021
What this trial is testing

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 208
Not applicableUnknownNCT04450030
What this trial is testing

Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University Hospital Muenster 204
Not applicableStudy completedNCT04546698
What this trial is testing

5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Acute RelapsingMultiple Sclerosis
Centre Hospitalier Régional d'Orléans 78
Post-approval studies (Phase 4)Study completedNCT03177083
What this trial is testing

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Biogen 80
Not applicableUnknownNCT05705986
What this trial is testing

Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS)

Who this might be right for
Relapse Remitting Multiple Sclerosis
Thomas Jefferson University 40
Post-approval studies (Phase 4)UnknownNCT01417273
What this trial is testing

Impact of Vitamin A on Multiple Sclerosis (MS)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Tehran University of Medical Sciences 100
Post-approval studies (Phase 4)Study completedNCT00493116
What this trial is testing

Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 20
Large-scale testing (Phase 3)Study completedNCT02753088
What this trial is testing

Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Biocad 158
Not applicableLooking for participantsNCT06390930
What this trial is testing

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive
Shirley Ryan AbilityLab 22
Not applicableStudy completedNCT01080001
What this trial is testing

A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina

Who this might be right for
Multiple Sclerosis, Relapsing-remitting
Merck KGaA, Darmstadt, Germany 71
Large-scale testing (Phase 3)Ended earlyNCT01633112
What this trial is testing

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Who this might be right for
Relapsing-remitting Multiple Sclerosis (RRMS)
Novartis Pharmaceuticals 1,064
Next Page